Individualized Response-adaptive Radiation Dose Prescription in HNC Based on MRI

Inclusion Criteria: * Age: older than 18 years * WHO (ECOG) performance status 0-2 * Histological proven HNC (squamous cell carcinoma) * HPV negative tumors or high risk HPV positive tumors * Stage III - IVB HNC of the hypopharynx, oropharynx and oral cavity according to UICC and AJCC guidelines * Tumor extension and localization suitable for radiochemotherapy with curative intent * Simultaneous standard chemotherapy with cisplatin applicable (no contra-indications) * Dental examination and -treatment before start of therapy * For women with childbearing potential and men in reproductive ages adequate contraception. * Ability of subject to understand character and individual consequences of the clinical trial * Written informed consent (must be available before enrolment in the trial) Exclusion Criteria: * Refusal of the patients to take part in the trial * Presence of distant metastases (UICC stage IVC) * HPV positive tumors UICC Stage III with T1/2 N3, despite of smoking status * Previous radiotherapy in the head and neck region * Second malignancy that is likely to require treatment during the trial intervention or follow-up period or that, in the opinion of the physician, has a considerable risk of recurrence or metastases within the follow-up period * Serious disease or medical condition with life expectancy of less than one year * Participation in competing interventional trial on cancer treatment * Patients who are not suitable for radiochemotherapy * Pregnant or lactating women * Patients not able to understand the character and individual consequences of the trial * Nasopharyngeal and glottis laryngeal carcinomas * Patients with contraindications for magnet-resonance tomography